Born: 1966
Title: Chief Medical Officer
Education: PhD, MD and specialist degree in oncology at Karolinska Institute/University hospital.
Employed: 2023
Background: Pia Baumann has substantial experience in drug development in the cancer field. Her experience comes from many years of clinical work at Karolinska Hospital and larger pharmaceutical companies as well as smaller biotech companies. Pia has developed global product strategies as well as designed and conducted clinical studies in close collaboration with leading clinics. Former Vice President Medical at AstraZeneca. Prior to that leading, global positions in cancer drug development at Takeda, Incyte and ARIAD Pharmaceuticals.
Shares in Medivir: 96,000 ordinary shares.
Warrants in Medivir: 0.
Born: 1974
Title: Chief Financial Officer.
Education: Degree of Bachelor of Science in Accounting and Finance.
Employed: 2019
Background: Over 20 years of experience in finance. Interim CEO at Medivir, May 2021-January 2022. Former CFO at O'Learys Trademark AB. Prior to that, Interim CFO at Rebtel and Head of Business Control at ICA Sverige AB. Before that held leading positions at Scan AB and SkiStar AB. Experience of working in listed-, private equity- and private companies.
Shares in Medivir: 238,000 ordinary shares.
Warrants in Medivir: 150,000
Born: 1971
Title: Chief Executive Officer
Education: Bachelor of Science in Business Administration
Employed: 2022
Background: 25 years of experience from pharmaceutical industry spanning global and local responsibilities. Has led product strategy development for late stage compounds preparing for regulatory approval and commercialisation as well as execution of launch for multiple compounds in specialty care. Primary area of focus in the past 10 years in the field of Oncology. Experience also includes interim CEO role for Sedana Medical AB and Director Investor Relations at AstraZeneca.
Chairman of the Board of Braincool AB.
Shares in Medivir: 668,000 ordinary shares.
Warrants in Medivir: 250,000.
Born: 1965
Title: Chief Scientific Officer
Education: PhD in Medical Science at Uppsala University
Employed: 2011
Background: More than 25 years of experience in cancer research. During the last 10 years focused on industrial drug discovery and development projects in oncology. Prior to that he managed an academic research group as principal investigator, and has initiated several innovative scientific projects in cancer biology. He has published more than 50 scientific articles and holds several patents. Adjunct professor at the Medical Faculty of Uppsala University.
Shares in Medivir: 123,908 ordinary shares
Warrants in Medivir: 100,000
Born: 1950 Title: Member of the Board since 2018, Chairman of the Board 2021-2026. Former CEO of Medivir AB.
Education: Pharmacist and Ph.D.
Background: Senior positions in major pharmaceutical and biotech companies for over 30 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public, multibillion dollar company. In the 1990s, he held senior positions at Astra AB, prior to which he was a Professor of Organic Chemistry at Uppsala University.
Other directorships: Member of the Board of Active Biotech.
Shares in Medivir: 4,000,000 ordinary shares.
Born: 1973.
Title: Member and Chairman of the Board since 2026.
Education: Master's degree in economics and Bachelor's degree in business administration from Lund University.
Background: Over 25 years of experience in healthcare investments. Previously a majority owner of the fund management company HealthInvest Partners AB. Earlier roles include analyst and portfolio manager specializing in the healthcare sector at Carnegie Investment Bank AB. Founder and owner of Hallberg Management AB.
Other directorships: Hallberg Management AB.
Shares in Medivir: 93,445,403 ordinary shares.
Born: 1973.
Title: Member of the Board since 2024.
Education: Ph.D. in Clinical Immunology from Uppsala University.
Background: More than 25 year’s academic drug development experience within immune oncology and is adjunct Professor of immunotherapy at Uppsala University. She is the CEO of Lokon Pharma since 2012 and a scientific advisor at venture cap Nexttobe. Further, she has >10 year’s board experience from privately owned biotech’s such as Chemilia, Bioimics and the public company Hansa Biopharma.
Other directorships: Chairperson of the Board of Repos Pharma. Member of the Board of Lokon Pharma.
Shares in Medivir: 6,309 ordinary shares.
Born: 1963.
Title: Member of the Board since 2024.
Education: PhD from Karolinska Institutet/MEB with a focus on statistics, MScs in pharmacy and mathematical statistics.
Background: Broad experience from drug development, especially regulatory affairs, from Regulatory Authorities, pharmaceutical companies and consultancy. Founder of the consulting company SDS Life Science which offers expert services within drug development and statistics. Great interest in the design of clinical studies and communication with authorities.
Other directorships: Member of the Boards of MedCap AB, Akiram Therapeutics, Attgeno AB and Lett Renovering AB.
Shares in Medivir: 0.